Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Off-patent drugs face low- to mid-single-digit price erosion year over year, and regulatory actions and competition in the drug supply chain could increase headwinds.